Rendering

Component: (Network and Table)
Network
128 - Disclosure - STOCK-BASED COMPENSATION (Tables)
(http://www.biosantepharma.com/role/StockbasedCompensationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001023024 (http://www.sec.gov/CIK)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
 
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs
The following table summarizes stock-based compensation expense incurred under the 2008 Plan and included in our consolidated statements of earnings:
 
(in thousands)
 
Years Ended December 31,
 
 
 
2016
 
2015
 
2014
 
Cost of sales
 
$
60
 
$
82
 
$
104
 
Research and development
 
$
112
 
$
109
 
$
69
 
Selling, general, and administrative
 
$
5,870
 
$
3,665
 
$
3,250
 
  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
For 2016, 2015, and 2014, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model, using the following weighted average assumptions:
 
 
 
Years Ended December 31,
 
 
 
2016
 
2015
 
2014
 
Expected option life (years)
 
5.50 - 6.25
 
5.50 - 6.25
 
5.39 - 6.25
 
Risk-free interest rate
 
1.14% - 1.55%
 
1.31% - 1.82%
 
1.55% - 2.03%
 
Expected stock price volatility
 
49.4% - 51.7%
 
47.9% - 50.5%
 
50.6% - 55.1%
 
Dividend yield
 
—
 
—
 
—
 
  
Schedule of Share-based Compansation, Stock Option And Restricted Stock, Activity
A summary of stock option activity under the Plan during the years ended December 31, 2016, 2015, and 2014 is presented below:
 
 
 
 
 
 
 
 
 
Weighted
 
 
 
 
 
 
 
 
 
Weighted
 
Average
 
 
 
 
 
 
 
Weighted
 
Average
 
Remaining
 
 
 
(in thousands, except per share and
 
Option
 
Average
 
Grant-date
 
Term
 
Aggregate
 
remaining term data)
 
Shares
 
Exercise Price
 
Fair Value
 
(years)
 
Intrinsic Value
 
Outstanding December 31, 2013
 
 
120
 
$
50.35
 
 
 
 
 
2.4
 
$
81
 
Granted
 
 
120
 
 
31.59
 
$
16.84
 
 
 
 
 
 
 
Options previously granted, approved by shareholders
 
 
325
 
 
6.39
 
 
 
 
 
 
 
 
 
 
Exercised
 
 
(43)
 
 
19.45
 
 
 
 
 
 
 
 
638
 
Forfeited
 
 
(4)
 
 
6.36
 
 
 
 
 
 
 
 
 
 
Expired
 
 
(60)
 
 
73.96
 
 
 
 
 
 
 
 
 
 
Outstanding December 31, 2014
 
 
458
 
$
14.44
 
 
 
 
 
8.7
 
$
19,472
 
Granted
 
 
138
 
 
62.07
 
$
30.08
 
 
 
 
 
 
 
Exercised
 
 
(89)
 
 
9.24
 
 
 
 
 
 
 
 
3,937
 
Forfeited
 
 
(33)
 
 
11.81
 
 
 
 
 
 
 
 
 
 
Expired
 
 
-
 
 
-
 
 
 
 
 
 
 
 
 
 
Outstanding December 31, 2015
 
 
474
 
$
29.40
 
 
 
 
 
8.2
 
$
10,136
 
Granted
 
 
265
 
 
45.60
 
$
22.45
 
 
 
 
 
 
 
Exercised
 
 
(127)
 
 
11.79
 
 
 
 
 
 
 
 
5,837
 
Forfeited
 
 
(32)
 
 
47.84
 
 
 
 
 
 
 
 
 
 
Expired
 
 
(2)
 
 
139.32
 
 
 
 
 
 
 
 
 
 
Outstanding December 31, 2016
 
 
578
 
$
39.28
 
 
 
 
 
8.2
 
$
12,928
 
Exercisable at December 31, 2016
 
 
128
 
$
30.87
 
 
 
 
 
7.1
 
$
4,033
 
Vested or expected to vest at December 31, 2016
 
 
567
 
$
39.11
 
 
 
 
 
8.2
 
$
12,776
 
  
Nonvested Restricted Stock Shares Activity
A summary of RSA activity under the Plan during the years ended December 31, 2016, 2015, and 2014 is presented below:
 
 
 
 
 
Weighted
 
 
 
 
 
 
 
Average Grant
 
Weighted Average
 
(in thousands, except per share and
 
 
 
Date  Fair
 
Remaining Term
 
remaining term data)
 
Shares
 
Value
 
(years)
 
Unvested at December 31, 2013
 
 
50
 
$
10.20
 
 
2.8
 
Granted
 
 
30
 
 
29.61
 
 
 
 
Vested
 
 
(17)
 
 
10.20
 
 
 
 
Forfeited
 
 
-
 
 
-
 
 
 
 
Unvested at December 31, 2014
 
 
63
 
$
19.34
 
 
2.6
 
Granted
 
 
28
 
 
67.26
 
 
 
 
Vested
 
 
(23)
 
 
15.82
 
 
 
 
Forfeited
 
 
(5)
 
 
19.41
 
 
 
 
Unvested at December 31, 2015
 
 
63
 
$
42.72
 
 
2.2
 
Granted
 
 
38
 
 
40.59
 
 
 
 
Vested
 
 
(30)
 
 
33.89
 
 
 
 
Forfeited
 
 
(8)
 
 
46.05
 
 
 
 
Unvested at December 31, 2016
 
 
63
 
$
45.72
 
 
2.2